Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.99
NYMX's Cash to Debt is ranked lower than
80% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. NYMX: 0.99 )
Ranked among companies with meaningful Cash to Debt only.
NYMX' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 10000.00 Max: No Debt
Current: 0.99
Equity to Asset -1.84
NYMX's Equity to Asset is ranked lower than
98% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NYMX: -1.84 )
Ranked among companies with meaningful Equity to Asset only.
NYMX' s Equity to Asset Range Over the Past 10 Years
Min: -7.82  Med: 0.28 Max: 1
Current: -1.84
-7.82
1
F-Score: 2
Z-Score: -207.91
M-Score: -101.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -10252.73
NYMX's Operating margin (%) is ranked lower than
93% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. NYMX: -10252.73 )
Ranked among companies with meaningful Operating margin (%) only.
NYMX' s Operating margin (%) Range Over the Past 10 Years
Min: -1233.17  Med: -821.69 Max: -145.43
Current: -10252.73
-1233.17
-145.43
Net-margin (%) -10357.27
NYMX's Net-margin (%) is ranked lower than
93% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. NYMX: -10357.27 )
Ranked among companies with meaningful Net-margin (%) only.
NYMX' s Net-margin (%) Range Over the Past 10 Years
Min: -1233.17  Med: -825.75 Max: -146.14
Current: -10357.27
-1233.17
-146.14
ROA (%) -2510.02
NYMX's ROA (%) is ranked lower than
99% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. NYMX: -2510.02 )
Ranked among companies with meaningful ROA (%) only.
NYMX' s ROA (%) Range Over the Past 10 Years
Min: -1675.32  Med: -185.45 Max: -95.34
Current: -2510.02
-1675.32
-95.34
ROC (Joel Greenblatt) (%) -453760.00
NYMX's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. NYMX: -453760.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYMX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -296533.33  Med: -41112.66 Max: -21833.33
Current: -453760
-296533.33
-21833.33
Revenue Growth (3Y)(%) -7.30
NYMX's Revenue Growth (3Y)(%) is ranked lower than
64% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. NYMX: -7.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYMX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.1  Med: 9.65 Max: 89.3
Current: -7.3
-10.1
89.3
EBITDA Growth (3Y)(%) 27.80
NYMX's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. NYMX: 27.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYMX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.1  Med: -0.20 Max: 28.8
Current: 27.8
-24.1
28.8
EPS Growth (3Y)(%) 27.60
NYMX's EPS Growth (3Y)(%) is ranked higher than
82% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. NYMX: 27.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYMX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.9  Med: 0.25 Max: 27.6
Current: 27.6
-23.9
27.6
» NYMX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

NYMX Guru Trades in

NYMX Guru Trades in

Q2 2014

NYMX Guru Trades in Q2 2014

Jim Simons 28,000 sh (+5.64%)
» More
Q3 2014

NYMX Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NYMX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CDTX, NAS:VCYT, NAS:ARGS, OTCPK:CLVLF, NAS:ECYT, OTCPK:CYDY, NAS:OVAS, NAS:AXSM, NAS:ARQL, NAS:SQNM, NAS:RDHL, NAS:GLYC, NAS:STML, NAS:KMDA, OTCPK:MDGEF, OTCPK:SLNCF, NAS:CARA, NAS:EARS, NAS:ANTH, AMEX:SYN » details
Traded in other countries:NYM.Germany,
Nymox Pharmaceutical Corp along with its subsidiaries is a biopharmaceutical corporation, engaged in research & development of diagnostics & drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease.

Nymox Pharmaceutical Corp was incorporated under the Canada Business Corporations Act in May 1995. The Company is a biopharmaceutical corporation engaged in research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease. It has three proprietary products on the market, and a significant R&D pipeline of products in development for the treatment of such conditions and diseases as BPH, prostate cancer, Alzheimer's disease or AD, E. coli O157; H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company also has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's products include: NicAlert, TobacAlert and AlzheimAlert. The Company has developed and markets NicAlert and TobacAlert, test strips for determining whether a person is using tobacco products or has been recently exposed to second-hand smoke. It has also developed AlzheimAlert, a proprietary urine assay that can aid physicians in the diagnosis of Alzheimer's disease. The Company is also developing NX-1207, treatments for BPH and prostate and liver cancer. It is also developing NXC-4720, novel antibacterial agents for the treatment of E. coli O157 bacterial contamination in meat and other food and drink products. Its AlzheimAlert test is certified with a CE Mark, making the device eligible for sale in the European Union. The Company's competitors include: Eli Lilly and Company, GE Healthcare, Athena Diagnostics, Inc., Fujirebio Europe NV, Amorfix Life Sciences Ltd, LabCorp, Quest Diagnostics, OraSure Technologies Inc., Abraxis LLC, Roche Diagnostics, Abbott and Diagnostic Products Corporation.

Ratios

vs
industry
vs
history
P/S 584.99
NYMX's P/S is ranked lower than
95% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. NYMX: 584.99 )
Ranked among companies with meaningful P/S only.
NYMX' s P/S Range Over the Past 10 Years
Min: 3.93  Med: 163.75 Max: 621.66
Current: 584.99
3.93
621.66
Current Ratio 0.78
NYMX's Current Ratio is ranked lower than
91% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NYMX: 0.78 )
Ranked among companies with meaningful Current Ratio only.
NYMX' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.59 Max: 42.02
Current: 0.78
0.12
42.02
Quick Ratio 0.77
NYMX's Quick Ratio is ranked lower than
88% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. NYMX: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
NYMX' s Quick Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.57 Max: 42.02
Current: 0.77
0.09
42.02
Days Inventory 101.11
NYMX's Days Inventory is ranked higher than
60% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. NYMX: 101.11 )
Ranked among companies with meaningful Days Inventory only.
NYMX' s Days Inventory Range Over the Past 10 Years
Min: 25.8  Med: 50.04 Max: 143.72
Current: 101.11
25.8
143.72
Days Sales Outstanding 4.98
NYMX's Days Sales Outstanding is ranked higher than
93% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. NYMX: 4.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
NYMX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.13  Med: 12.79 Max: 57.91
Current: 4.98
0.13
57.91
Days Payable 1.00
NYMX's Days Payable is ranked lower than
96% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. NYMX: 1.00 )
Ranked among companies with meaningful Days Payable only.
NYMX' s Days Payable Range Over the Past 10 Years
Min: 806.78  Med: 1903.00 Max: 4197.5
Current: 1
806.78
4197.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.58
NYMX's Price/Median PS Value is ranked lower than
91% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. NYMX: 3.58 )
Ranked among companies with meaningful Price/Median PS Value only.
NYMX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 1.36 Max: 3.87
Current: 3.58
0.03
3.87
Earnings Yield (Greenblatt) (%) -14.41
NYMX's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. NYMX: -14.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NYMX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -46.2  Med: 0.00 Max: 0
Current: -14.41
-46.2
0

More Statistics

Revenue (TTM) (Mil) $0.22
EPS (TTM) $ -0.59
Beta1.13
Short Percentage of Float6.04%
52-Week Range $1.13 - 4.37
Shares Outstanding (Mil)44.79
» More Articles for NYMX

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data Jun 23 2016
Here’s Why These Five Stocks Are on the Move Today Jun 22 2016
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 Jun 22 2016
Why Nymox Pharmaceutical Took Off Jun 22 2016
Nymox stock halted ahead of release of positive prostate cancer-prevention results Jun 22 2016
Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged... Jun 22 2016
Nymox reports 1Q loss May 16 2016
Nymox reports 1Q loss May 16 2016
Nymox Pharmaceutical Corporation (NYMX) and 2 Banks Witness Notable Insider Buying Apr 18 2016
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 12 2016
NYMOX PHARMACEUTICAL CORP Financials Apr 06 2016
Nymox Files Current Financial Statements Jan 05 2016
Nymox Provides Update From Shareholders Annual General Meeting December 16 Dec 17 2015
5 Stocks Insiders Love Right Now Dec 09 2015
Analyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology,... Nov 23 2015
4 Biotech Stocks Under $10 to Trade for Breakouts Aug 11 2015
Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online Aug 10 2015
Nymox Announces Appointment of James G. Robinson to Board of Directors Aug 05 2015
Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results Jul 28 2015
Nymox Appoints Cutler & Co. as Auditor Jul 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)